"CRISPR: A Screener's Guide" headlines the March edition of SLAS Discovery

February 24, 2020

Oak Brook, IL - The March edition of SLAS Discovery features the cover article, "CRISPR: A Screener's Guide," by Carlos le Sage, Ph.D., Steffen Lawo, Ph.D., and Benedict C.S. Cross, Ph.D., (Horizon Discovery, United Kingdom). In their review, the authors discuss how CRISPR-Cas9 systems are being used widely throughout the drug discovery process and the development of new precision medicines.

The discovery of CRISPR-Cas9 systems has helped ignite gene editing adoption and has greatly impacted pharmaceutical and biotechnology research. Because of the CRISPR-Cas9 discovery, gene editing can be used at an industrial scale to identify and validate new biological targets for precision medicines, with functional genomic screening also having an increasingly important role. CRISPR screens provide more robust data sets for target identification and validation, and identify potential mechanisms of drug resistance and sensitivity ahead of new drugs entering clinical trials.

The March cover article also examines the developing landscape for CRISPR screening technologies within the pharmaceutical industry and explores the next steps for this constantly evolving screening platform.
Access to "CRISPR: A Screener's Guide" is available indefinitely via SAGE Open Access at https://journals.sagepub.com/toc/jbxb/25/3. A bonus article also featured in this edition of SLAS Discovery, "Forced Self-Modification Assays as a Strategy to Screen MonoPARP Enzymes," is also available via SAGE Open Access at https://journals.sagepub.com/doi/full/10.1177/2472555219883623.

For more information about SLAS and its journals, visit http://www.slas.org/journals.

SLAS (Society for Laboratory Automation and Screening) is an international community of 16,000 professionals and students dedicated to life sciences discovery and technology. The SLAS mission is to bring together researchers in academia, industry and government to advance life sciences discovery and technology via education, knowledge exchange and global community building.

SLAS Discovery: Advancing the Science of Drug Discovery, 2018 Impact Factor 2.192. Editor-in-Chief Robert M. Campbell, Ph.D., Eli Lilly and Company, Indianapolis, IN (USA).

SLAS Technology: Translating Life Sciences Innovation, 2018 Impact Factor 2.048. Editor-in-Chief Edward Kai-Hua Chow, Ph.D., National University of Singapore (Singapore).

Contact Information:

Jill Hronek, Director of Marketing Communications
Telephone: +1.630.256.7527, ext. 103
E-mail: jhronek@slas.org

SLAS (Society for Laboratory Automation and Screening)

Related Crispr Articles from Brightsurf:

Media alert: new articles in the CRISPR Journal
The CRISPR Journal announces the publication of its October 2020 issue.

CRISPR-based malaria testing on-the-fly
A multi-disciplinary research collaboration which was led by Harvard's Wyss Institute for Biologically Inspired Engineering and the Massachusetts Institute of Technology (MIT), created a field-applicable, ultrasensitive diagnostic assay that specifically detects DNA sequences from all Plasmodium species in symptomatic and asymptomatic malaria.

Barcoding long DNA quantifies CRISPR effects
A sequencing approach can home in on a rare mutation within a large number of cells, revealing implications for CRISPR genome editing and early cancer detection.

Researchers map mechanisms in the largest CRISPR system
The largest and most complex CRISPR system has been visualized by researchers from the University of Copenhagen in a new study.

Listeria protein provides a CRISPR 'kill switch'
A single protein derived from a common strain of bacteria found in the soil will offer scientists a more precise way to edit RNA.

Comparing 13 different CRISPR-Cas9 DNA scissors
IBS scientists have achieved the most extensive high-throughput analysis of CRISPR-Cas9 activities.

New CRISPR advance may solve key quandary
A mutation unique to certain cancer tumors is a potential homing beacon for safely deploying CRISPR gene editing enzymes to disarm DNA that makes cancer cells resistant to treatment, while ignoring the gene in normal cells where it's critical to healthy function, according to to a new study from ChristianaCare's Gene Editing Institute in the journal Molecular Cancer Research.

Directed protein evolution with CRISPR-Cas9
New area of application for gene scissors: Optimized proteins for biomedical research.

CRISPR a tool for conservation, not just gene editing
The gene-editing technology CRISPR has been used for a variety of agricultural and public health purposes -- from growing disease-resistant crops to, more recently, a diagnostic test for the virus that causes COVID-19.

Diagnostics, meet CRISPR
A new diagnostic test to quickly and easily monitor kidney transplant patients for infection and rejection relies on a simple urine sample and a powerful partner: the gene-editing technology CRISPR.

Read More: Crispr News and Crispr Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.